Funder: Breakthrough T1D
Due Dates: December 4, 2025 (LOI) | February 12, 2026 (Full Proposal, by invitation)
Funding Amounts: Up to $900,000 total for up to 3 years; indirect costs not permitted for IDDP applications.
Summary: Supports for-profit organizations developing innovative technologies for continuous C-peptide monitoring in type 1 diabetes, aligned with Breakthrough T1D priorities.
Key Information: Company matching funds required; contact Breakthrough T1D prior to LOI submission.